Holen Sie sich die Stockscreener-App
3.46
6.49%
-0.24
Handel nachbörslich:
3.60
0.14
+4.05%
Schlusskurs vom Vortag:
$3.70
Offen:
$3.71
24-Stunden-Volumen:
432.72K
Relative Volume:
2.07
Marktkapitalisierung:
$117.72M
Einnahmen:
$210.00K
Nettoeinkommen (Verlust:
$-10.12M
KGV:
-11.41
EPS:
-0.3032
Netto-Cashflow:
$-7.12M
1W Leistung:
+0.00%
1M Leistung:
+24.01%
6M Leistung:
+12.34%
1J Leistung:
+7.45%
1-Tages-Spanne:
$3.33
$3.82
1-Wochen-Bereich:
$3.33
$3.89
52-Wochen-Spanne:
$2.32
$5.4566
Anixa Biosciences Inc Stock (ANIX) Company Profile
Firmenname
Anixa Biosciences Inc
Sektor
Branche
Telefon
408-708-9808
Adresse
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Compare ANIX vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
3.46 | 125.89M | 210.00K | -10.12M | -7.12M | -0.3032 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-21 | Eingeleitet | Maxim Group | Buy |
| 2022-12-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2021-04-12 | Eingeleitet | H.C. Wainwright | Buy |
Anixa Biosciences Inc Aktie (ANIX) Neueste Nachrichten
Anixa Biosciences (ANIX) CEO purchases 3,188 shares at $3.37 each - Stock Titan
Form 4 Anixa Biosciences Inc For: 27 July By Investing.com - Investing.com Canada
Anixa Biosciences CEO Amit Kumar buys $11,190 in company stock By Investing.com - Investing.com Canada
Anixa Biosciences CEO Amit Kumar buys $11,190 in company stock - Investing.com
Anixa Biosciences Inc (ANIX) CEO purchases 3,000 shares at $3.73 - Stock Titan
Anixa Biosciences, Inc. Revenue Breakdown – NASDAQ:ANIX - TradingView
Anixa Biosciences Inc (ANIX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ANIX|Anixa Biosciences Inc|Price:3.700|Chg%:-0.050 - TradingKey
TradingKey - TradingKey
ANIX|Anixa Biosciences Inc|Price:3.725|Chg%:+0.025 - TradingKey
ANIX|Anixa Biosciences Inc|Price:3.680|Chg%:-0.020 - TradingKey
Anixa Biosciences Inc (ANIX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Anixa Biosciences Inc (ANIX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Anixa Biosciences (ANIX) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance UK
New Strong Buy Stocks for July 22nd - The Globe and Mail
CEO Amit Kumar Increases Stake in Anixa Biosciences Inc - GuruFocus
3 Penny Stocks With Market Caps Over $100M To Consider - Sahm
Anixa Biosciences (ANIX) CEO buys 5,000 common shares - Stock Titan
Anixa Biosciences Inc. (ANIX) Q2 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline Advances - dars.gov.et
Anixa Biosciences CEO Amit Kumar acquires 5,000 common shares for $17,300 - Bitget
Insider Buying: Titterton Lewis H Jr Acquires Additional Shares of Anixa Biosciences Inc (ANIX) - GuruFocus
Anixa Biosciences (ANIX) director purchases 12,000 shares of common stock - Stock Titan
Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance - AOL.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Anixa Biosciences Director Lewis H. Titterton Jr acquires $9,172 of common shares - Bitget
Anixa Biosciences director buys $9,174 in common stock By Investing.com - Investing.com South Africa
Insider Buying: Titterton Lewis H Jr Increases Stake in Anixa Bi - GuruFocus
Anixa Biosciences director buys $9,174 in common stock - Investing.com
Form 4 Anixa Biosciences Inc For: 16 July By Investing.com - Investing.com Canada
Director Lewis Titterton buys more Anixa Biosciences Inc (ANIX) stock - Stock Titan
Anixa Biosciences (ANIX) Secures New Patent for Breast Cancer Va - GuruFocus
Anixa Biosciences Secures Patent Approval in Australia for Breas - GuruFocus
Anixa Biosciences (ANIX) Secures New Patent for Breast Cancer Vaccine Technology - GuruFocus
Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology - PR Newswire
Anixa Biosciences (ANIX) Faces Modest Decline, Testing Key Support at $2.89Percent Above MA - dars.gov.et
CEO Amit Kumar Increases Stake in Anixa Biosciences Inc with Rec - GuruFocus
Form 4 Anixa Biosciences Inc For: 13 July By Investing.com - Investing.com Nigeria
Anixa Biosciences CEO Amit Kumar buys $15,200 in stock By Investing.com - Investing.com Canada
Anixa Biosciences (ANIX) CEO Amit Kumar buys 5,000 shares at $3.04 - Stock Titan
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Trial to Highest Dose Cohort - HLTH
Anixa Biosciences Treats First Patient in Fifth Cohort of Ovarian Cancer CAR-T Clinical Trial - Moomoo
Anixa doses first patient in highest cohort of ovarian trial By Investing.com - Investing.com South Africa
Anixa doses first patient in highest cohort of ovarian trial - Investing.com
Anixa Biosciences announced that in its clinical trial of CAR-T cell therapy, no dose-limiting toxicities were observed up to the previously established 3x10⁶/kg dose level. - Bitget
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date - PR Newswire
ANIXAnixa Biosciences Inc Revenue Breakdown - Finviz
D. Boral Capital Initiates Anixa Biosciences(ANIX.US) With Buy Rating, Announces Target Price $10 - Moomoo
Here's why you should add ANIX stock to your portfolio now - MSN
ANIX Assumed by D. Boral Capital -- Rating Maintained at Buy - GuruFocus
Anixa Biosciences Price Target Maintained With a $10.00/Share by D. Boral Capital - Moomoo
Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040 - AOL.com
Finanzdaten der Anixa Biosciences Inc-Aktie (ANIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):